{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:32:42Z","timestamp":1792402362788,"version":"4.4.0"},"reference-count":391,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:00:00Z","timestamp":1642291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002003"],"award-info":[{"award-number":["UL1TR002003"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["20PRE35150022"],"award-info":[{"award-number":["20PRE35150022"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32AG57468"],"award-info":[{"award-number":["T32AG57468"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.apsb.2022.01.011","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T12:23:32Z","timestamp":1643027012000},"page":"995-1018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Remembering your A, B, C's: Alzheimer's disease and ABCA1"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4929-7389","authenticated-orcid":false,"given":"Cutler T.","family":"Lewandowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan S.","family":"Laham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.J.","family":"Thatcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2022.01.011_bib1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/alz.12068","article-title":"2020 Alzheimer's disease facts and figures","volume":"16","author":"Alzheimer\u2019s","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.apsb.2022.01.011_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","article-title":"2016 Alzheimer's disease facts and figures","volume":"12","author":"Alzheimer's","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.apsb.2022.01.011_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","article-title":"Drug treatments in Alzheimer's disease","volume":"16","author":"Briggs","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.apsb.2022.01.011_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1756285612461679","article-title":"Current and future treatments for Alzheimer's disease","volume":"6","author":"Yiannopoulou","year":"2013","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.apsb.2022.01.011_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer's disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimer's Res Ther"},{"key":"10.1016\/j.apsb.2022.01.011_bib6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40266-013-0108-6","article-title":"Successes and failures for drugs in late-stage development for Alzheimer's disease","volume":"30","author":"Berk","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.apsb.2022.01.011_bib7","doi-asserted-by":"crossref","first-page":"e12050","DOI":"10.1002\/trc2.12050","article-title":"Alzheimer's disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.apsb.2022.01.011_bib8","first-page":"e12095","article-title":"Clinical and biomarker trajectories in sporadic Alzheimer's disease: a longitudinal study","volume":"12","author":"Wang","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.apsb.2022.01.011_bib9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2022.01.011_bib10","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","article-title":"Neuropathology of older persons without cognitive impairment from two community-based studies","volume":"66","author":"Bennett","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.apsb.2022.01.011_bib11","doi-asserted-by":"crossref","first-page":"844","DOI":"10.2174\/15672050113109990157","article-title":"Resilient brain aging: characterization of discordance between Alzheimer's disease pathology and cognition","volume":"10","author":"Negash","year":"2013","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib12","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jamapsychiatry.2020.1807","article-title":"Cortical proteins associated with cognitive resilience in community-dwelling older persons","volume":"77","author":"Yu","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.apsb.2022.01.011_bib13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ana.25266","article-title":"Targeted brain proteomics uncover multiple pathways to Alzheimer's dementia","volume":"84","author":"Yu","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.apsb.2022.01.011_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/geronb\/gbaa135","article-title":"Associations between personality traits and cognitive resilience in older adults","volume":"76","author":"Graham","year":"2021","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"10.1016\/j.apsb.2022.01.011_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12877-018-0984-z","article-title":"Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study","volume":"18","author":"Legdeur","year":"2018","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.apsb.2022.01.011_bib16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41588-018-0311-9","article-title":"Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk","volume":"51","author":"Jansen","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2022.01.011_bib17","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1093\/brain\/awaa209","article-title":"Genetic variants and functional pathways associated with resilience to Alzheimer's disease","volume":"143","author":"Dumitrescu","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2022.01.011_bib18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1212\/WNL.0b013e3181eee25f","article-title":"Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study","volume":"75","author":"Matsuzaki","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.apsb.2022.01.011_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1515\/bmc-2016-0029","article-title":"Alzheimer's disease as an inflammatory disease","volume":"8","author":"Bolos","year":"2017","journal-title":"Biomol Concepts"},{"key":"10.1016\/j.apsb.2022.01.011_bib20","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2022.01.011_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.neuropharm.2017.11.014","article-title":"Connecting Alzheimer's disease to diabetes: underlying mechanisms and potential therapeutic targets","volume":"136","author":"Vieira","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.apsb.2022.01.011_bib22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/epirev\/mxs012","article-title":"Type 2 diabetes as a risk factor for Alzheimer's disease: the confounders, interactions, and neuropathology associated with this relationship","volume":"35","author":"Vagelatos","year":"2013","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.apsb.2022.01.011_bib23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jcjd.2016.07.003","article-title":"Effects of diabetes mellitus on cognitive decline in patients with Alzheimer disease: a systematic review","volume":"41","author":"Li","year":"2017","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.apsb.2022.01.011_bib24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2337\/dc15-1588","article-title":"Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia","volume":"39","author":"Chatterjee","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.apsb.2022.01.011_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.dadm.2017.01.005","article-title":"Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis","volume":"7","author":"Santos","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.apsb.2022.01.011_bib26","doi-asserted-by":"crossref","first-page":"l4414","DOI":"10.1136\/bmj.l4414","article-title":"Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study","volume":"366","author":"Sabia","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.apsb.2022.01.011_bib27","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s11892-014-0476-2","article-title":"Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions","volume":"14","author":"Jayaraman","year":"2014","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.apsb.2022.01.011_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archneurol.2007.29","article-title":"Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the cardiovascular health study cognition study","volume":"65","author":"Irie","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.apsb.2022.01.011_bib29","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.2337\/diabetes.51.4.1256","article-title":"Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia aging study","volume":"51","author":"Peila","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.01.011_bib30","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archneur.59.11.1737","article-title":"Dementia and Alzheimer disease incidence: a prospective cohort study","volume":"59","author":"Kukull","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.apsb.2022.01.011_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/alzrt181","article-title":"Dementia in the oldest old: a multi-factorial and growing public health issue","volume":"5","author":"Gardner","year":"2013","journal-title":"Alzheimer's Res Ther"},{"key":"10.1016\/j.apsb.2022.01.011_bib32","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.3390\/ijms19102937","article-title":"Ageing, cellular senescence and neurodegenerative disease","volume":"19","author":"Kritsilis","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2022.01.011_bib33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/CIA.S158513","article-title":"Oxidative stress, aging, and diseases","volume":"13","author":"Liguori","year":"2018","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.apsb.2022.01.011_bib34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature08983","article-title":"Neural mechanisms of ageing and cognitive decline","volume":"464","author":"Bishop","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.01.011_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0891988710383571","article-title":"Genetics of Alzheimer disease","volume":"23","author":"Bekris","year":"2010","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.apsb.2022.01.011_bib36","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","article-title":"Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation","volume":"26","author":"Oakley","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib37","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/373523a0","article-title":"Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein","volume":"373","author":"Games","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.01.011_bib38","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/383710a0","article-title":"Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1","volume":"383","author":"Duff","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.01.011_bib39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nm0198-097","article-title":"Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes","volume":"4","author":"Holcomb","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2022.01.011_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.274.5284.99","article-title":"Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice","volume":"274","author":"Hsiao","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.01.011_bib41","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/sj.embor.7400784","article-title":"Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology","volume":"7","author":"Radde","year":"2006","journal-title":"EMBO Rep"},{"key":"10.1016\/j.apsb.2022.01.011_bib42","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1523\/JNEUROSCI.20-11-04050.2000","article-title":"High-level neuronal expression of abeta 1\u201342 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation","volume":"20","author":"Mucke","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1389-0344(01)00067-3","article-title":"Co-expression of multiple transgenes in mouse CNS: a comparison of strategies","volume":"17","author":"Jankowsky","year":"2001","journal-title":"Biomol Eng"},{"key":"10.1016\/j.apsb.2022.01.011_bib44","doi-asserted-by":"crossref","first-page":"104811","DOI":"10.1016\/j.nbd.2020.104811","article-title":"Alzheimer's disease pathology in APOE transgenic mouse models: the who, what, when, where, why, and how","volume":"139","author":"Lewandowski","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib45","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","article-title":"Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction","volume":"39","author":"Oddo","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2022.01.011_bib46","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.neurobiolaging.2003.08.012","article-title":"Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease","volume":"24","author":"Oddo","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.apsb.2022.01.011_bib47","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1111\/ejn.13442","article-title":"Human tau increases amyloid beta plaque size but not amyloid beta-mediated synapse loss in a novel mouse model of Alzheimer's disease","volume":"44","author":"Jackson","year":"2016","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13024-017-0231-7","article-title":"Practical considerations for choosing a mouse model of Alzheimer's disease","volume":"12","author":"Jankowsky","year":"2017","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.apsb.2022.01.011_bib49","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fnagi.2018.00382","article-title":"A novel hAPP\/htau mouse model of Alzheimer's disease: inclusion of APP with tau exacerbates behavioral deficits and zinc administration heightens tangle pathology","volume":"10","author":"Lippi","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib50","doi-asserted-by":"crossref","first-page":"12754","DOI":"10.1074\/jbc.RA119.009487","article-title":"Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation","volume":"294","author":"Saito","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib51","doi-asserted-by":"crossref","first-page":"13168","DOI":"10.3390\/ijms222313168","article-title":"A review of the current mammalian models of Alzheimer's disease and challenges that need to be overcome","volume":"22","author":"Mckean","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2022.01.011_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2020.07.007","article-title":"Relevance of transgenic mouse models for Alzheimer's disease","volume":"177","author":"Tai","year":"2021","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.apsb.2022.01.011_bib53","doi-asserted-by":"crossref","first-page":"e12114","DOI":"10.1002\/trc2.12114","article-title":"Translational animal models for Alzheimer's disease: an Alzheimer's Association Business Consortium Think Tank","volume":"6","author":"Vitek","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.apsb.2022.01.011_bib54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/gim.2015.117","article-title":"The genetic landscape of Alzheimer disease: clinical implications and perspectives","volume":"18","author":"Van Cauwenberghe","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.apsb.2022.01.011_bib55","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","article-title":"TREM2\u2014a key player in microglial biology and Alzheimer disease","volume":"14","author":"Ulland","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.apsb.2022.01.011_bib56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimer's disease","volume":"368","author":"Jonsson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.01.011_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci8020027","article-title":"ABCA7 and pathogenic pathways of Alzheimer's disease","volume":"8","author":"Aikawa","year":"2018","journal-title":"Brain Sci"},{"key":"10.1016\/j.apsb.2022.01.011_bib58","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/ng.3246","article-title":"Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease","volume":"47","author":"Steinberg","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2022.01.011_bib59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer's disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.01.011_bib60","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1179\/1743132814Y.0000000376","article-title":"Association study of TREM2 polymorphism rs75932628 with late-onset Alzheimer's disease in Chinese Han population","volume":"36","author":"Ma","year":"2014","journal-title":"Neurol Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib61","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3233\/JAD-140225","article-title":"Lack of genetic association between TREM2 and late-onset Alzheimer's disease in a Japanese population","volume":"41","author":"Miyashita","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib62","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13024-015-0016-9","article-title":"TREM2 is associated with increased risk for Alzheimer's disease in African Americans","volume":"10","author":"Jin","year":"2015","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.apsb.2022.01.011_bib63","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000430842","article-title":"Association study of the TREM2 gene and identification of a novel variant in exon 2 in Iranian patients with late-onset Alzheimer's disease","volume":"24","author":"Mehrjoo","year":"2015","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.apsb.2022.01.011_bib64","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/YPG.0000000000000188","article-title":"Lack of association between triggering receptor expressed on myeloid cells 2 polymorphism rs75932628 and late-onset Alzheimer's disease in a Chinese Han population","volume":"28","author":"Wang","year":"2018","journal-title":"Psychiatr Genet"},{"key":"10.1016\/j.apsb.2022.01.011_bib65","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.genom.1.1.507","article-title":"Apolipoprotein E: far more than a lipid transport protein","volume":"1","author":"Mahley","year":"2000","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.apsb.2022.01.011_bib66","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.01.011_bib67","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium","volume":"278","author":"Farrer","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2022.01.011_bib68","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.apsb.2022.01.011_bib69","doi-asserted-by":"crossref","first-page":"50380","DOI":"10.1074\/jbc.M204898200","article-title":"Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease","volume":"277","author":"Morrow","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib70","doi-asserted-by":"crossref","first-page":"19053","DOI":"10.1074\/jbc.271.32.19053","article-title":"Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins","volume":"271","author":"Dong","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib71","doi-asserted-by":"crossref","first-page":"11657","DOI":"10.1021\/bi000099m","article-title":"Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain","volume":"39","author":"Morrow","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.apsb.2022.01.011_bib72","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2217\/17460875.3.5.505","article-title":"Apolipoprotein E and cholesterol in aging and disease in the brain","volume":"3","author":"de Chaves","year":"2008","journal-title":"Future Lipidol"},{"key":"10.1016\/j.apsb.2022.01.011_bib73","doi-asserted-by":"crossref","first-page":"e93120","DOI":"10.1371\/journal.pone.0093120","article-title":"Extracellular proteolysis of apolipoprotein E (apoE) by secreted serine neuronal protease","volume":"9","author":"Tamboli","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.01.011_bib74","doi-asserted-by":"crossref","first-page":"14908","DOI":"10.3390\/ijms140714908","article-title":"Proteolytic cleavage of apolipoprotein E4 as the keystone for the heightened risk associated with Alzheimer's disease","volume":"14","author":"Rohn","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2022.01.011_bib75","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","article-title":"Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report","volume":"25","author":"Arboleda-Velasquez","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2022.01.011_bib76","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1172\/JCI113096","article-title":"Apolipoprotein E2-Christchurch (136 Arg\u2192Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia","volume":"80","author":"Wardell","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2022.01.011_bib77","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ana.24135","article-title":"Sex modifies the APOE-related risk of developing Alzheimer disease","volume":"75","author":"Altmann","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.apsb.2022.01.011_bib78","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaneurol.2017.2188","article-title":"Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis","volume":"74","author":"Neu","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.apsb.2022.01.011_bib79","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1212\/WNL.53.9.1937","article-title":"Diabetes mellitus and the risk of dementia: the Rotterdam study","volume":"53","author":"Ott","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.apsb.2022.01.011_bib80","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jalz.2016.07.152","article-title":"Systematic evaluation of the associations between environmental risk factors and dementia: an umbrella review of systematic reviews and meta-analyses","volume":"13","author":"Bellou","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.apsb.2022.01.011_bib81","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1073\/pnas.0230450100","article-title":"Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in\u00a0vivo","volume":"100","author":"Farris","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.01.011_bib82","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1474-4422(20)30231-3","article-title":"Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches","volume":"19","author":"Kellar","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2022.01.011_bib83","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10571-015-0233-3","article-title":"Role of RAGE in Alzheimer's disease","volume":"36","author":"Cai","year":"2016","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.apsb.2022.01.011_bib84","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.bbadis.2015.11.013","article-title":"The role of insulin in the vascular contributions to age-related dementia","volume":"1862","author":"Hughes","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2022.01.011_bib85","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jalz.2010.08.228","article-title":"Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia","volume":"7","author":"Roher","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.apsb.2022.01.011_bib86","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41593-020-0635-5","article-title":"Shared proteomic effects of cerebral atherosclerosis and Alzheimer's disease on the human brain","volume":"23","author":"Wingo","year":"2020","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib87","doi-asserted-by":"crossref","first-page":"e28263","DOI":"10.1371\/journal.pone.0028263","article-title":"Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid beta levels in humans","volume":"6","author":"Zetterberg","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.01.011_bib88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-006-0136-y","article-title":"Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles","volume":"113","author":"Beach","year":"2007","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.apsb.2022.01.011_bib89","doi-asserted-by":"crossref","first-page":"e011146","DOI":"10.1161\/JAHA.118.011146","article-title":"Apolipoprotein E genotype modifies the association between cardiac output and cognition in older adults","volume":"8","author":"Bown","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.apsb.2022.01.011_bib90","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1212\/WNL.45.3.555","article-title":"Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease","volume":"45","author":"Mayeux","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.apsb.2022.01.011_bib91","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/ntr\/ntv075","article-title":"Interaction of cigarette smoking history with APOE genotype and age on amyloid level, glucose metabolism, and neurocognition in cognitively normal elders","volume":"18","author":"Durazzo","year":"2016","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib92","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.trci.2019.02.007","article-title":"Patients with Alzheimer's disease who carry the APOE epsilon4 allele benefit more from physical exercise","volume":"5","author":"Jensen","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.apsb.2022.01.011_bib93","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1001\/jama.298.11.1300","article-title":"Association of apolipoprotein E genotypes with lipid levels and coronary risk","volume":"298","author":"Bennet","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2022.01.011_bib94","doi-asserted-by":"crossref","first-page":"3912175","DOI":"10.1155\/2016\/3912175","article-title":"Apolipoprotein E gene variants and risk of coronary heart disease: a meta-analysis","volume":"2016","author":"Xu","year":"2016","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.apsb.2022.01.011_bib95","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12933-016-0329-1","article-title":"Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease","volume":"15","author":"El-Lebedy","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.apsb.2022.01.011_bib96","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing","volume":"51","author":"Kunkle","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2022.01.011_bib97","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/ijmr.IJMR_473_17","article-title":"New genetic players in late-onset Alzheimer's disease: findings of genome-wide association studies","volume":"148","author":"Misra","year":"2018","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib98","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/labinvest.3780421","article-title":"ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation","volume":"82","author":"Wellington","year":"2002","journal-title":"Lab Invest"},{"key":"10.1016\/j.apsb.2022.01.011_bib99","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/01.wnr.0000221833.41340.cd","article-title":"Quantitation of ATP-binding cassette subfamily\u2014a transporter gene expression in primary human brain cells","volume":"17","author":"Kim","year":"2006","journal-title":"Neuroreport"},{"key":"10.1016\/j.apsb.2022.01.011_bib100","doi-asserted-by":"crossref","first-page":"15137","DOI":"10.1074\/jbc.M100474200","article-title":"ATP-binding cassette transporter A1 contains an NH2-terminal signal anchor sequence that translocates the protein's first hydrophilic domain to the exoplasmic space","volume":"276","author":"Fitzgerald","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib101","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/01.ATV.0000054662.44688.9A","article-title":"HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol","volume":"23","author":"Oram","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib102","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-2275(20)31588-1","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"42","author":"Dean","year":"2001","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib103","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1152\/physrev.00005.2005","article-title":"ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease","volume":"85","author":"Oram","year":"2005","journal-title":"Physiol Rev"},{"key":"10.1016\/j.apsb.2022.01.011_bib104","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1006\/bbrc.2000.4219","article-title":"Apolipoprotein specificity for lipid efflux by the human ABCAI transporter","volume":"280","author":"Remaley","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2022.01.011_bib105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1172\/JCI118082","article-title":"Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease","volume":"96","author":"Francis","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2022.01.011_bib106","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1124\/pr.119.017897","article-title":"Brothers in arms: ABCA1- and ABCG1-mediated cholesterol efflux as promising targets in cardiovascular disease treatment","volume":"72","author":"Frambach","year":"2020","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.apsb.2022.01.011_bib107","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00041433-200104000-00003","article-title":"Cholesterol metabolism in the brain","volume":"12","author":"Dietschy","year":"2001","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.apsb.2022.01.011_bib108","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1161\/ATVBAHA.116.307023","article-title":"Central nervous system lipoproteins: ApoE and regulation of cholesterol metabolism","volume":"36","author":"Mahley","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib109","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0014-5793(90)81107-Y","article-title":"Rates of cholesterol, ubiquinone, dolichol and dolichyl-P biosynthesis in rat brain slices","volume":"269","author":"Andersson","year":"1990","journal-title":"FEBS Lett"},{"key":"10.1016\/j.apsb.2022.01.011_bib110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1471-4159.2009.05917.x","article-title":"Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats","volume":"109","author":"Nieweg","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2022.01.011_bib111","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hipo.20743","article-title":"Cholesterol homeostasis markers are localized to mouse hippocampal pyramidal and granule layers","volume":"20","author":"Valdez","year":"2010","journal-title":"Hippocampus"},{"key":"10.1016\/j.apsb.2022.01.011_bib112","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13238-014-0131-3","article-title":"Cholesterol metabolism and homeostasis in the brain","volume":"6","author":"Zhang","year":"2015","journal-title":"Protein Cell"},{"key":"10.1016\/j.apsb.2022.01.011_bib113","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0304-3940(95)11763-M","article-title":"ApoE immunoreactivity and microglial cells in Alzheimer's disease brain","volume":"195","author":"Uchihara","year":"1995","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.apsb.2022.01.011_bib114","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1523\/JNEUROSCI.5476-05.2006","article-title":"Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus","volume":"26","author":"Xu","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib115","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0005-2760(87)90295-5","article-title":"Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins","volume":"917","author":"Pitas","year":"1987","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2022.01.011_bib116","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0896-6273(93)90070-8","article-title":"Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions","volume":"11","author":"Rebeck","year":"1993","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2022.01.011_bib117","doi-asserted-by":"crossref","first-page":"292598","DOI":"10.1155\/2012\/292598","article-title":"Cholesterol: its regulation and role in central nervous system disorders","volume":"2012","author":"Orth","year":"2012","journal-title":"Cholesterol"},{"key":"10.1016\/j.apsb.2022.01.011_bib118","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1074\/jbc.M116.714485","article-title":"Convergent signaling pathways controlled by LRP1 (receptor-related protein 1) cytoplasmic and extracellular domains limit cellular cholesterol accumulation","volume":"291","author":"El Asmar","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib119","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1471-4159.2010.07002.x","article-title":"Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain","volume":"115","author":"Zlokovic","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2022.01.011_bib120","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.bbalip.2016.09.011","article-title":"Cholesterol 24-hydroxylase: brain cholesterol metabolism and beyond","volume":"1861","author":"Moutinho","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2022.01.011_bib121","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1093\/hmg\/dds296","article-title":"Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease","volume":"21","author":"Cruchaga","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.apsb.2022.01.011_bib122","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.1523\/JNEUROSCI.1972-08.2008","article-title":"Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels","volume":"28","author":"Riddell","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib123","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1002\/jnr.22073","article-title":"Mechanism underlying apolipoprotein E (ApoE) isoform-dependent lipid efflux from neural cells in culture","volume":"87","author":"Minagawa","year":"2009","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib124","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.neuron.2018.05.008","article-title":"APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived brain cell types","volume":"98","author":"Lin","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2022.01.011_bib125","doi-asserted-by":"crossref","first-page":"e0166195","DOI":"10.1371\/journal.pone.0166195","article-title":"Differential effects of apoE4 and activation of ABCA1 on brain and plasma lipoproteins","volume":"11","author":"Boehm-Cagan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.01.011_bib126","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1093\/hmg\/ddx155","article-title":"APOE epsilon4\/epsilon4 diminishes neurotrophic function of human iPSC-derived astrocytes","volume":"26","author":"Zhao","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.apsb.2022.01.011_bib127","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13024-016-0099-y","article-title":"Apolipoprotein E lipoprotein particles inhibit amyloid-beta uptake through cell surface heparan sulphate proteoglycan","volume":"11","author":"Fu","year":"2016","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.apsb.2022.01.011_bib128","doi-asserted-by":"crossref","first-page":"14813","DOI":"10.1073\/pnas.1106420108","article-title":"Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions","volume":"108","author":"Chen","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.01.011_bib129","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/1873-3468.13428","article-title":"Apolipoprotein E associated with reconstituted high-density lipoprotein-like particles is protected from aggregation","volume":"593","author":"Hubin","year":"2019","journal-title":"FEBS Lett"},{"key":"10.1016\/j.apsb.2022.01.011_bib130","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s11064-018-2629-1","article-title":"Understanding the role of ApoE fragments in Alzheimer's disease","volume":"44","author":"Munoz","year":"2019","journal-title":"Neurochem Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib131","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1750-1326-9-2","article-title":"Soluble apoE\/Abeta complex: mechanism and therapeutic target for APOE4-induced AD risk","volume":"9","author":"Tai","year":"2014","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.apsb.2022.01.011_bib132","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1326-9-60","article-title":"Increasing membrane cholesterol of neurons in culture recapitulates Alzheimer's disease early phenotypes","volume":"9","author":"Marquer","year":"2014","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.apsb.2022.01.011_bib133","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1074\/jbc.M112.442103","article-title":"Levels of soluble apolipoprotein E\/amyloid-beta (Abeta) complex are reduced and oligomeric Abeta increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples","volume":"288","author":"Tai","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib134","doi-asserted-by":"crossref","first-page":"15181","DOI":"10.1523\/JNEUROSCI.1542-12.2012","article-title":"Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide","volume":"32","author":"Hashimoto","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib135","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/brain\/aws127","article-title":"Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta","volume":"135","author":"Koffie","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2022.01.011_bib136","doi-asserted-by":"crossref","first-page":"e995","DOI":"10.1038\/tp.2016.252","article-title":"Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration","volume":"7","author":"Hoglund","year":"2017","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.apsb.2022.01.011_bib137","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.dadm.2019.01.010","article-title":"ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid-beta copathology","volume":"11","author":"Koriath","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.apsb.2022.01.011_bib138","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neurobiolaging.2015.09.011","article-title":"Association of APOE with tau-tangle pathology with and without beta-amyloid","volume":"37","author":"Farfel","year":"2016","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.apsb.2022.01.011_bib139","doi-asserted-by":"crossref","first-page":"40987","DOI":"10.1074\/jbc.M407963200","article-title":"ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE","volume":"279","author":"Wahrle","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib140","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1523\/JNEUROSCI.4741-08.2009","article-title":"Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function","volume":"29","author":"Karasinska","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib141","doi-asserted-by":"crossref","first-page":"41197","DOI":"10.1074\/jbc.M407962200","article-title":"Deficiency of ABCA impairs apolipoprotein E metabolism in brain","volume":"279","author":"Hirsch-Reinshagen","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib142","doi-asserted-by":"crossref","first-page":"43243","DOI":"10.1074\/jbc.M508781200","article-title":"The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease","volume":"280","author":"Hirsch-Reinshagen","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib143","doi-asserted-by":"crossref","first-page":"9611","DOI":"10.1523\/JNEUROSCI.1400-19.2019","article-title":"ApoE4 alters ABCA1 membrane trafficking in astrocytes","volume":"39","author":"Rawat","year":"2019","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib144","first-page":"671","article-title":"Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease","volume":"118","author":"Wahrle","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2022.01.011_bib145","doi-asserted-by":"crossref","first-page":"34144","DOI":"10.1074\/jbc.M110.108100","article-title":"ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein\/presenilin 1 mice","volume":"285","author":"Donkin","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib146","doi-asserted-by":"crossref","first-page":"13125","DOI":"10.1523\/JNEUROSCI.1937-12.2012","article-title":"Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice","volume":"32","author":"Fitz","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib147","doi-asserted-by":"crossref","first-page":"e00006","DOI":"10.1042\/AN20090015","article-title":"Memory deficits in APP23\/Abca1+\/\u2013 mice correlate with the level of A\u03b2 oligomers","volume":"1","author":"Lefterov","year":"2009","journal-title":"ASN Neuro"},{"key":"10.1016\/j.apsb.2022.01.011_bib148","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","article-title":"ApoE promotes the proteolytic degradation of A\u03b2","volume":"58","author":"Jiang","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2022.01.011_bib149","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0305799101","article-title":"Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease","volume":"101","author":"Cutler","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.01.011_bib150","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0304-3940(01)02277-7","article-title":"On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells","volume":"314","author":"Bogdanovic","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.apsb.2022.01.011_bib151","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0304-3940(00)01466-X","article-title":"Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases","volume":"293","author":"Bretillon","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.apsb.2022.01.011_bib152","doi-asserted-by":"crossref","first-page":"e002886","DOI":"10.1161\/JAHA.115.002886","article-title":"ABCA1-mediated cholesterol efflux capacity to cerebrospinal fluid is reduced in patients with mild cognitive impairment and Alzheimer's disease","volume":"5","author":"Yassine","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.apsb.2022.01.011_bib153","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s11011-020-00577-4","article-title":"Association of genetic variants of ABCA1 with susceptibility to dementia: (SADEM study)","volume":"35","author":"Teresa","year":"2020","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib154","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0197-4580(02)00094-5","article-title":"ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease","volume":"24","author":"Wollmer","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.apsb.2022.01.011_bib155","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.neurobiolaging.2006.04.005","article-title":"Gender-specific association of ATP-binding cassette transporter 1 (ABCA1) polymorphisms with the risk of late-onset Alzheimer's disease","volume":"28","author":"Sundar","year":"2007","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.apsb.2022.01.011_bib156","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jalz.2015.04.006","article-title":"Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease","volume":"11","author":"Nordestgaard","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.apsb.2022.01.011_bib157","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","article-title":"Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner","volume":"178","author":"Jaitin","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2022.01.011_bib158","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41593-019-0566-1","article-title":"Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain","volume":"23","author":"Marschallinger","year":"2020","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib159","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.cmet.2020.03.015","article-title":"New microglia on the block","volume":"31","author":"Jung","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2022.01.011_bib160","doi-asserted-by":"crossref","first-page":"108572","DOI":"10.1016\/j.celrep.2020.108572","article-title":"ApoE4 impairs neuron-astrocyte coupling of fatty acid metabolism","volume":"34","author":"Qi","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2022.01.011_bib161","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.cell.2019.04.001","article-title":"Neuron\u2013astrocyte metabolic coupling protects against activity-induced fatty acid toxicity","volume":"177","author":"Ioannou","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2022.01.011_bib162","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2014.05.007","article-title":"ATP-binding cassette transporter A1: from metabolism to neurodegeneration","volume":"72 Pt A","author":"Koldamova","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib163","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3389\/fnagi.2019.00370","article-title":"Revealing a novel landscape of the association between blood lipid levels and Alzheimer's disease: a meta-analysis of a case-control study","volume":"11","author":"Tang","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib164","series-title":"Endotext","article-title":"Introduction to lipids and lipoproteins","author":"Feingold","year":"2000"},{"key":"10.1016\/j.apsb.2022.01.011_bib165","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib166","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.119.316206","article-title":"Atherogenic lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation","volume":"126","author":"Schnitzler","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib167","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1194\/jlr.R800034-JLR200","article-title":"The metabolism and anti-atherogenic properties of HDL","volume":"50 Suppl","author":"Rye","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib168","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0022-2275(20)41536-6","article-title":"The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function","volume":"33","author":"Segrest","year":"1992","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib169","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nri3793","article-title":"Cholesterol, inflammation and innate immunity","volume":"15","author":"Tall","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2022.01.011_bib170","doi-asserted-by":"crossref","first-page":"e004808","DOI":"10.1161\/JAHA.116.004808","article-title":"Association of cholesterol efflux capacity with clinical features of metabolic syndrome: relevance to atherosclerosis","volume":"5","author":"Gall","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.apsb.2022.01.011_bib171","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cardiores.2005.07.003","article-title":"Oxidized LDL downregulates ATP-binding cassette transporter-1 in human vascular endothelial cells via inhibiting liver X receptor (LXR)","volume":"68","author":"Zhu","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib172","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1161\/CIRCRESAHA.114.303454","article-title":"Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase","volume":"114","author":"Shao","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib173","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MOL.0b013e32833c1ef6","article-title":"Marked HDL deficiency and premature coronary heart disease","volume":"21","author":"Schaefer","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.apsb.2022.01.011_bib174","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2337\/db07-0484","article-title":"Association of the ATP-binding cassette transporter A1 R230C variant with early-onset type 2 diabetes in a Mexican population","volume":"57","author":"Villarreal-Molina","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.01.011_bib175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.trsl.2009.12.002","article-title":"The role of ATP-binding-cassette-transporter-A1 (ABCA1) gene polymorphism on coronary artery disease risk","volume":"155","author":"Doosti","year":"2010","journal-title":"Transl Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib176","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1055\/a-0583-0201","article-title":"A meta-analysis of the associations between the ATP-binding cassette transporter ABCA1 R219K (rs2230806) polymorphism and the risk of type 2 diabetes in Asians","volume":"50","author":"Jung","year":"2018","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib177","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-016-1547-z","article-title":"The role of APOE in cerebrovascular dysfunction","volume":"131","author":"Tai","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.apsb.2022.01.011_bib178","doi-asserted-by":"crossref","first-page":"184042","DOI":"10.1155\/2012\/184042","article-title":"Dyslipidemia and blood\u2013brain barrier integrity in Alzheimer's disease","volume":"2012","author":"Bowman","year":"2012","journal-title":"Curr Gerontol Geriatr Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib179","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JAD-2005-7107","article-title":"Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer\u2019s disease\u2014is this type 3 diabetes?.","volume":"7","author":"Steen","year":"2005","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib180","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2022.01.011_bib181","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1471-4159.2005.03269.x","article-title":"Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-d-aspartate receptor and phosphatidyl-inositol-3-kinase-dependent manner","volume":"94","author":"van der Heide","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2022.01.011_bib182","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/B978-0-12-385506-0.00004-1","article-title":"Insulin, synaptic function, and opportunities for neuroprotection","volume":"98","author":"Mielke","year":"2011","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.apsb.2022.01.011_bib183","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1073\/pnas.0809158106","article-title":"Protection of synapses against Alzheimer\u2019s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers","volume":"106","author":"De Felice","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.01.011_bib184","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3233\/JAD-180263","article-title":"Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis","volume":"65","author":"Campbell","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib185","doi-asserted-by":"crossref","first-page":"37","DOI":"10.14336\/AD.2017.1202","article-title":"Metformin and the risk of dementia in type 2 diabetes patients","volume":"10","author":"Chin-Hsiao","year":"2019","journal-title":"Aging Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib186","doi-asserted-by":"crossref","first-page":"e963","DOI":"10.1210\/clinem\/dgz234","article-title":"Metformin and risk of Alzheimer's disease among community-dwelling people with diabetes: a national case-control study","volume":"105","author":"Sluggett","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.01.011_bib187","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JAD-150493","article-title":"Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial","volume":"51","author":"Luchsinger","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib188","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WAD.0000000000000202","article-title":"Effects of the insulin sensitizer metformin in Alzheimer disease: pilot data from a randomized placebo-controlled crossover study","volume":"31","author":"Koenig","year":"2017","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.apsb.2022.01.011_bib189","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3233\/JAD-141791","article-title":"Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia","volume":"44","author":"Claxton","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib190","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Gold","year":"2010","journal-title":"Dement Geriatr Cognit Disord"},{"key":"10.1016\/j.apsb.2022.01.011_bib191","first-page":"29","article-title":"Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys","volume":"47","author":"Maeshiba","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.apsb.2022.01.011_bib192","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.euroneuro.2014.06.008","article-title":"Type 3 diabetes is sporadic Alzheimers disease: mini-review","volume":"24","author":"de la Monte","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.apsb.2022.01.011_bib193","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5551\/jat.E599","article-title":"Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations","volume":"16","author":"Koseki","year":"2009","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.apsb.2022.01.011_bib194","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.celrep.2017.05.032","article-title":"Hepatocyte ABCA1 deletion impairs liver insulin signaling and lipogenesis","volume":"19","author":"Key","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2022.01.011_bib195","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.2337\/db11-0081","article-title":"Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules","volume":"60","author":"Kruit","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.01.011_bib196","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1194\/jlr.M045294","article-title":"ABCA1 in adipocytes regulates adipose tissue lipid content, glucose tolerance, and insulin sensitivity","volume":"55","author":"de Haan","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib197","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1194\/jlr.M064303","article-title":"Hematopoietic ABCA1 deletion promotes monocytosis and worsens diet-induced insulin resistance in mice","volume":"57","author":"Tang","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib198","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/DMSO.S186565","article-title":"ATP-binding cassette transporter A1 (ABCA1) expression in adipose tissue and its modulation with insulin resistance in obesity","volume":"12","author":"Vincent","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.apsb.2022.01.011_bib199","doi-asserted-by":"crossref","first-page":"e22142","DOI":"10.1371\/journal.pone.0022142","article-title":"Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function","volume":"6","author":"Patel","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.01.011_bib200","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer's disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.apsb.2022.01.011_bib201","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.neuroscience.2013.07.009","article-title":"Molecular links between Alzheimer's disease and diabetes mellitus","volume":"250","author":"Yang","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.apsb.2022.01.011_bib202","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bbr.2016.08.047","article-title":"TLR4 is a link between diabetes and Alzheimer's disease","volume":"316","author":"Huang","year":"2017","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib203","doi-asserted-by":"crossref","DOI":"10.1177\/1759091417719201","article-title":"Peripheral inflammation, apolipoprotein E4, and amyloid-beta interact to induce cognitive and cerebrovascular dysfunction","volume":"9","author":"Marottoli","year":"2017","journal-title":"ASN Neuro"},{"key":"10.1016\/j.apsb.2022.01.011_bib204","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12974-016-0666-8","article-title":"High-fat diet feeding differentially affects the development of inflammation in the central nervous system","volume":"13","author":"Guillemot-Legris","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.apsb.2022.01.011_bib205","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1101\/lm.051839.120","article-title":"Identifying the molecular systems that influence cognitive resilience to Alzheimer's disease in genetically diverse mice","volume":"27","author":"Heuer","year":"2020","journal-title":"Learn Mem"},{"key":"10.1016\/j.apsb.2022.01.011_bib206","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nbd.2018.10.009","article-title":"Distinct cytokine profiles in human brains resilient to Alzheimer's pathology","volume":"121","author":"Barroeta-Espar","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib207","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.biopsych.2010.06.012","article-title":"A meta-analysis of cytokines in Alzheimer's disease","volume":"68","author":"Swardfager","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.apsb.2022.01.011_bib208","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000097202","article-title":"Passage of cytokines across the blood\u2013brain barrier","volume":"2","author":"Banks","year":"1995","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.apsb.2022.01.011_bib209","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/cns.13569","article-title":"Peripheral inflammation and blood\u2013brain barrier disruption: effects and mechanisms","volume":"27","author":"Huang","year":"2021","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.apsb.2022.01.011_bib210","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1530\/VB-19-0033","article-title":"Immune cell trafficking across the blood\u2013brain barrier in the absence and presence of neuroinflammation","volume":"2","author":"Marchetti","year":"2020","journal-title":"Vasc Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib211","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1471-4159.1989.tb07399.x","article-title":"Reduced glucose transporter at the blood\u2013brain barrier and in cerebral cortex in Alzheimer disease","volume":"53","author":"Kalaria","year":"1989","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2022.01.011_bib212","doi-asserted-by":"crossref","first-page":"10837","DOI":"10.1073\/pnas.162350199","article-title":"Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice","volume":"99","author":"Wyss-Coray","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.01.011_bib213","doi-asserted-by":"crossref","first-page":"8354","DOI":"10.1523\/JNEUROSCI.0616-08.2008","article-title":"Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice","volume":"28","author":"Hickman","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib214","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2009.02.003","article-title":"Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: effects of oligomeric and fibrillar amyloid-beta","volume":"210","author":"Michelucci","year":"2009","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.apsb.2022.01.011_bib215","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI57256","article-title":"An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers","volume":"122","author":"Bomfim","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2022.01.011_bib216","first-page":"136","article-title":"Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease","volume":"3","author":"Wang","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.apsb.2022.01.011_bib217","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1523\/JNEUROSCI.21-04-01179.2001","article-title":"beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis","volume":"21","author":"Combs","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib218","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1742-2094-3-21","article-title":"Apolipoprotein E isoform-dependent dendritic recovery of hippocampal neurons following activation of innate immunity","volume":"3","author":"Maezawa","year":"2006","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.apsb.2022.01.011_bib219","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/glia.22289","article-title":"APOE genotype alters glial activation and loss of synaptic markers in mice","volume":"60","author":"Zhu","year":"2012","journal-title":"Glia"},{"key":"10.1016\/j.apsb.2022.01.011_bib220","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1742-2094-11-111","article-title":"Human APOE4 increases microglia reactivity at Abeta plaques in a mouse model of Abeta deposition","volume":"11","author":"Rodriguez","year":"2014","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.apsb.2022.01.011_bib221","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/jnc.13072","article-title":"APOE-modulated Abeta-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective","volume":"133","author":"Tai","year":"2015","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2022.01.011_bib222","doi-asserted-by":"crossref","first-page":"e183597","DOI":"10.1001\/jamanetworkopen.2018.3597","article-title":"Association of chronic low-grade inflammation with risk of Alzheimer disease in ApoE4 carriers","volume":"1","author":"Tao","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.apsb.2022.01.011_bib223","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.nbd.2013.01.018","article-title":"ABCA1 influences neuroinflammation and neuronal death","volume":"54","author":"Karasinska","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib224","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1161\/ATVBAHA.114.304959","article-title":"Increased systemic and plaque inflammation in ABCA1 mutation carriers with attenuation by statins","volume":"35","author":"Bochem","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib225","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/CIRCULATIONAHA.108.793869","article-title":"Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions","volume":"118","author":"Yvan-Charvet","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2022.01.011_bib226","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1194\/jlr.M006486","article-title":"Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol","volume":"51","author":"Zhu","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib227","doi-asserted-by":"crossref","first-page":"e08009","DOI":"10.7554\/eLife.08009","article-title":"LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling","volume":"4","author":"Ito","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.apsb.2022.01.011_bib228","doi-asserted-by":"crossref","first-page":"32336","DOI":"10.1074\/jbc.M109.047472","article-title":"The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor","volume":"284","author":"Tang","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib229","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0076-6879(86)28096-9","article-title":"Synthetic peptide analogs of apolipoproteins","volume":"128","author":"Anantharamaiah","year":"1986","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.apsb.2022.01.011_bib230","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1006\/geno.1994.1237","article-title":"Cloning of two novel ABC transporters mapping on human chromosome 9","volume":"21","author":"Luciani","year":"1994","journal-title":"Genomics"},{"key":"10.1016\/j.apsb.2022.01.011_bib231","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1620\/tjem.220.223","article-title":"D-4F, an apolipoprotein A-I mimetic peptide, promotes cholesterol efflux from macrophages via ATP-binding cassette transporter A1","volume":"220","author":"Xie","year":"2010","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.apsb.2022.01.011_bib232","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1194\/jlr.R051367","article-title":"Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review","volume":"55","author":"White","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib233","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3390\/biom10091276","article-title":"The role of HDL and HDL mimetic peptides as potential therapeutics for Alzheimer's disease","volume":"10","author":"Chernick","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.apsb.2022.01.011_bib234","doi-asserted-by":"crossref","first-page":"10248","DOI":"10.1016\/S0021-9258(17)39238-4","article-title":"Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine","volume":"260","author":"Anantharamaiah","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib235","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0022-2275(20)31599-6","article-title":"Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide","volume":"42","author":"Datta","year":"2001","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib236","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/01.CIR.0000134275.90823.87","article-title":"Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice","volume":"109","author":"Navab","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2022.01.011_bib237","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/hc0302.103711","article-title":"Oral administration of an Apo A-I mimetic peptide synthesized from d-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol","volume":"105","author":"Navab","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2022.01.011_bib238","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/jnc.14554","article-title":"High-density lipoprotein mimetic peptide 4F mitigates amyloid-beta-induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia","volume":"147","author":"Chernick","year":"2018","journal-title":"J Neurochem"},{"key":"10.1016\/j.apsb.2022.01.011_bib239","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.nbd.2009.03.007","article-title":"Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease","volume":"34","author":"Handattu","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib240","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1194\/jlr.M600214-JLR200","article-title":"D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet","volume":"47","author":"Buga","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib241","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1089\/neu.2006.0192","article-title":"COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury","volume":"24","author":"Laskowitz","year":"2007","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.apsb.2022.01.011_bib242","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/exnr.2001.7541","article-title":"Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides","volume":"167","author":"Laskowitz","year":"2001","journal-title":"Exp Neurol"},{"key":"10.1016\/j.apsb.2022.01.011_bib243","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/bi991209w","article-title":"The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts","volume":"39","author":"Datta","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.apsb.2022.01.011_bib244","doi-asserted-by":"crossref","first-page":"e0131997","DOI":"10.1371\/journal.pone.0131997","article-title":"Novel apoE-derived ABCA1 agonist peptide (CS-6253) promotes reverse cholesterol transport and induces formation of prebeta-1 HDL in vitro","volume":"10","author":"Hafiane","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.01.011_bib245","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1194\/jlr.M003665","article-title":"A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice","volume":"51","author":"Bielicki","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib246","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/jcph.853","article-title":"Phase 1 randomized, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics of a single escalating dose and repeated doses of CN-105 in healthy adult subjects","volume":"57","author":"Guptill","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2022.01.011_bib247","doi-asserted-by":"crossref","first-page":"146685","DOI":"10.1016\/j.brainres.2020.146685","article-title":"ApoE mimetic improves pathology and memory in a model of Alzheimer's disease","volume":"1733","author":"Krishnamurthy","year":"2020","journal-title":"Brain Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib248","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1101\/gr.2160004","article-title":"Genomic analysis of the nuclear receptor family: new insights into structure, regulation, and evolution from the rat genome","volume":"14","author":"Zhang","year":"2004","journal-title":"Genome Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib249","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0039-128X(99)00014-8","article-title":"The structure of the nuclear hormone receptors","volume":"64","author":"Kumar","year":"1999","journal-title":"Steroids"},{"key":"10.1016\/j.apsb.2022.01.011_bib250","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1021\/acsptsci.8b00029","article-title":"Advances in orphan nuclear receptor pharmacology: a new era in drug discovery","volume":"1","author":"de Vera","year":"2018","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.apsb.2022.01.011_bib251","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1194\/jlr.M200235-JLR200","article-title":"cAMP induces ABCA1 phosphorylation activity and promotes cholesterol efflux from fibroblasts","volume":"43","author":"Haidar","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib252","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1189\/jlb.0709513","article-title":"A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux","volume":"87","author":"Bingham","year":"2010","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib253","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1194\/jlr.M085886","article-title":"Angiotensin II induces cholesterol accumulation and impairs insulin secretion by regulating ABCA1 in beta cells","volume":"59","author":"Lyu","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib254","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.7150\/ijbs.29741","article-title":"The nuclear export and ubiquitin\u2013proteasome-dependent degradation of PPARgamma induced by angiotensin II","volume":"15","author":"Sun","year":"2019","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.apsb.2022.01.011_bib255","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/ATVBAHA.109.202309","article-title":"Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice","volume":"30","author":"Ishii","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib256","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/01.ATV.0000117178.94087.ba","article-title":"Verapamil increases the apolipoprotein-mediated release of cellular cholesterol by induction of ABCA1 expression via Liver X receptor-independent mechanism","volume":"24","author":"Suzuki","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib257","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/aps.2010.139","article-title":"AMPK in cardiovascular health and disease","volume":"31","author":"Shirwany","year":"2010","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2022.01.011_bib258","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.2337\/diabetes.51.8.2420","article-title":"The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism","volume":"51","author":"Hawley","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.01.011_bib259","doi-asserted-by":"crossref","first-page":"33499","DOI":"10.1074\/jbc.M110.159772","article-title":"Adenosine monophosphate-activated protein kinase induces cholesterol efflux from macrophage-derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice","volume":"285","author":"Li","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biocel.2016.06.014","article-title":"AMPK activates LXRalpha and ABCA1 expression in human macrophages","volume":"78","author":"Kemmerer","year":"2016","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib261","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/pr.115.011395","article-title":"Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes","volume":"68","author":"Graaf","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.apsb.2022.01.011_bib262","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.bbrc.2015.11.054","article-title":"Glucagon-like peptide 1 (GLP-1)-based therapy upregulates LXR\u2013ABCA1\/ABCG1 cascade in adipocytes","volume":"468","author":"Mostafa","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2022.01.011_bib263","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12933-019-0954-6","article-title":"Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1\/2 pathway","volume":"18","author":"Wu","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.apsb.2022.01.011_bib264","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1159\/000494235","article-title":"Glucagon-like peptide-1 modulates cholesterol homeostasis by suppressing the miR-19b-induced downregulation of ABCA1","volume":"50","author":"Yao","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.apsb.2022.01.011_bib265","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.molmet.2019.12.015","article-title":"Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes","volume":"34","author":"Lyu","year":"2020","journal-title":"Mol Metab"},{"key":"10.1016\/j.apsb.2022.01.011_bib266","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13063-019-3259-x","article-title":"Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)","volume":"20","author":"Femminella","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.apsb.2022.01.011_bib267","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11883-013-0325-9","article-title":"GPR109A and vascular inflammation","volume":"15","author":"Chai","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.apsb.2022.01.011_bib268","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1124\/pr.110.003301","article-title":"International Union of Basic and Clinical Pharmacology. LXXXII: nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B)","volume":"63","author":"Offermanns","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.apsb.2022.01.011_bib269","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.cellsig.2013.06.008","article-title":"Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential","volume":"25","author":"Gaidarov","year":"2013","journal-title":"Cell Signal"},{"key":"10.1016\/j.apsb.2022.01.011_bib270","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1194\/jlr.M020917","article-title":"Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells","volume":"53","author":"Zhang","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib271","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s13311-018-00704-1","article-title":"Prostaglandin A1 inhibits the cognitive decline of APP\/PS1 transgenic mice via PPARgamma\/ABCA1-dependent cholesterol efflux mechanisms","volume":"16","author":"Xu","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.apsb.2022.01.011_bib272","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s13311-019-00731-6","article-title":"Cholesterol 24-hydroxylation by CYP46A1: benefits of modulation for brain diseases","volume":"16","author":"Petrov","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.apsb.2022.01.011_bib273","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.stem.2018.12.013","article-title":"Cholesterol metabolism Is a druggable axis that independently regulates tau and amyloid-beta in iPSC-derived Alzheimer's disease neurons","volume":"24","author":"van der Kant","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.apsb.2022.01.011_bib274","doi-asserted-by":"crossref","first-page":"14284","DOI":"10.1021\/bi035512f","article-title":"Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain","volume":"42","author":"Mast","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.apsb.2022.01.011_bib275","doi-asserted-by":"crossref","first-page":"31783","DOI":"10.1074\/jbc.M110.143313","article-title":"Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain","volume":"285","author":"Mast","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib276","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1021\/acs.jmedchem.9b01383","article-title":"In\u00a0vitro activation of cytochrome P450 46A1 (CYP46A1) by efavirenz-related compounds","volume":"63","author":"Mast","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib277","doi-asserted-by":"crossref","first-page":"7183","DOI":"10.3390\/molecules16097183","article-title":"Identification of dehydroxytrichostatin A as a novel up-regulator of the ATP-binding cassette transporter A1 (ABCA1)","volume":"16","author":"Xu","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2022.01.011_bib278","doi-asserted-by":"crossref","first-page":"105059","DOI":"10.1016\/j.phrs.2020.105059","article-title":"Enhancing PPARgamma by HDAC inhibition reduces foam cell formation and atherosclerosis in ApoE deficient mice","volume":"160","author":"Gao","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib279","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.bbrc.2014.11.029","article-title":"Inhibiting epigenetic enzymes to improve atherogenic macrophage functions","volume":"455","author":"Van den Bossche","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2022.01.011_bib280","doi-asserted-by":"crossref","first-page":"e0194661","DOI":"10.1371\/journal.pone.0194661","article-title":"Class I HDAC inhibition is a novel pathway for regulating astrocytic apoE secretion","volume":"13","author":"Dresselhaus","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.01.011_bib281","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/pro.3496","article-title":"The nuclear receptor superfamily: a structural perspective","volume":"27","author":"Weikum","year":"2018","journal-title":"Protein Sci"},{"key":"10.1016\/j.apsb.2022.01.011_bib282","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1128\/MCB.22.16.5782-5792.2002","article-title":"Functional evidence for retinoid X receptor (RXR) as a nonsilent partner in the thyroid hormone receptor\/RXR heterodimer","volume":"22","author":"Li","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib283","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/MCB.06175-11","article-title":"Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor alpha in mouse liver reveals extensive sharing of binding sites","volume":"32","author":"Boergesen","year":"2012","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib284","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1097-2765(01)00164-2","article-title":"A PPAR gamma\u2013LXR\u2013ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis","volume":"7","author":"Chawla","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2022.01.011_bib285","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.bcp.2008.08.005","article-title":"The RXR agonists PA024 and HX630 have different abilities to activate LXR\/RXR and to induce ABCA1 expression in macrophage cell lines","volume":"76","author":"Nishimaki-Mogami","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2022.01.011_bib286","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/386407a0","article-title":"Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists","volume":"386","author":"Mukherjee","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.01.011_bib287","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/01.ATV.0000248101.93488.84","article-title":"The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia","volume":"26","author":"Lalloyer","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib288","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1161\/ATVBAHA.109.189506","article-title":"Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR\/LXR heterodimer in the liver","volume":"29","author":"Lalloyer","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib289","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","article-title":"ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models","volume":"335","author":"Cramer","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.01.011_bib290","doi-asserted-by":"crossref","DOI":"10.1126\/science.1235809","article-title":"Comment on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d","volume":"340","author":"Fitz","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.01.011_bib291","doi-asserted-by":"crossref","DOI":"10.1126\/science.1234089","article-title":"Comment on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d","volume":"340","author":"Price","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.01.011_bib292","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233937","article-title":"Comment on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d","volume":"340","author":"Tesseur","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.01.011_bib293","doi-asserted-by":"crossref","DOI":"10.1126\/science.1235505","article-title":"Comment on \u201cApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models\u201d","volume":"340","author":"Veeraraghavalu","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.01.011_bib294","doi-asserted-by":"crossref","first-page":"30538","DOI":"10.1074\/jbc.M114.600833","article-title":"Amyloid-beta pathology and APOE genotype modulate retinoid X receptor agonist activity in\u00a0vivo","volume":"289","author":"Tai","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib295","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.apsb.2022.01.011_bib296","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-016-0173-2","article-title":"Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimer's Res Ther"},{"key":"10.1016\/j.apsb.2022.01.011_bib297","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1021\/acs.molpharmaceut.8b00096","article-title":"Retinoid X receptor alpha nitro-ligand Z-10 and its optimized derivative Z-36 reduce beta-amyloid plaques in Alzheimer's disease mouse model","volume":"16","author":"Ren","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2022.01.011_bib298","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbadis.2018.10.028","article-title":"OAB-14, a bexarotene derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing beta-amyloid clearance in APP\/PS1 mice","volume":"1865","author":"Yuan","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib299","doi-asserted-by":"crossref","first-page":"e14387","DOI":"10.14814\/phy2.14387","article-title":"FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR-B1-deficient mice fed a high-fat and high-cholesterol diet","volume":"8","author":"Singh","year":"2020","journal-title":"Physiol Rep"},{"key":"10.1016\/j.apsb.2022.01.011_bib300","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/aps.2014.116","article-title":"Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis","volume":"36","author":"Jiao","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2022.01.011_bib301","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bbalip.2012.02.004","article-title":"Retinoic acid receptor agonists regulate expression of ATP-binding cassette transporter G1 in macrophages","volume":"1821","author":"Ayaori","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2022.01.011_bib302","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"J Adv Pharm Technol Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib303","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/83348","article-title":"PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway","volume":"7","author":"Chinetti","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2022.01.011_bib304","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.atherosclerosis.2009.01.008","article-title":"On the mechanism for PPAR agonists to enhance ABCA1 gene expression","volume":"205","author":"Ogata","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.apsb.2022.01.011_bib305","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.01.011_bib306","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543784.2017.1312339","article-title":"PPAR-alpha agonists are still on the rise: an update on clinical and experimental findings","volume":"26","author":"Ferri","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.apsb.2022.01.011_bib307","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3233\/ADR-190104","article-title":"Gemfibrozil, a lipid-lowering drug, lowers amyloid plaque pathology and enhances memory in a mouse model of Alzheimer's disease via peroxisome proliferator-activated receptor alpha","volume":"3","author":"Chandra","year":"2019","journal-title":"J Alzheimers Dis Rep"},{"key":"10.1016\/j.apsb.2022.01.011_bib308","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41366-018-0011-7","article-title":"GQ-11: a new PPAR agonist improves obesity-induced metabolic alterations in LDLr\u2013\/\u2013 mice","volume":"42","author":"Silva","year":"2018","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.apsb.2022.01.011_bib309","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbrc.2018.08.125","article-title":"E3317 promotes cholesterol efflux in macrophage cells via enhancing ABCA1 expression","volume":"504","author":"Wang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2022.01.011_bib310","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1073\/pnas.091021198","article-title":"A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport","volume":"98","author":"Oliver","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.01.011_bib311","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3233\/JAD-190864","article-title":"An exploratory Phase IIa study of the PPAR delta\/gamma agonist T3D-959 assessing metabolic and cognitive function in subjects with mild to moderate Alzheimer's disease","volume":"73","author":"Chamberlain","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib312","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1124\/jpet.103.064535","article-title":"Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in\u00a0vivo","volume":"309","author":"Beyer","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2022.01.011_bib313","doi-asserted-by":"crossref","first-page":"2010675","DOI":"10.1155\/2018\/2010675","article-title":"Signaling mechanisms of selective PPARgamma modulators in Alzheimer's disease","volume":"2018","author":"Govindarajulu","year":"2018","journal-title":"PPAR Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib314","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.bbrc.2017.06.146","article-title":"INT131 increases dendritic arborization and protects against Abeta toxicity by inducing mitochondrial changes in hippocampal neurons","volume":"490","author":"Godoy","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2022.01.011_bib315","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1677\/JOE-09-0271","article-title":"Liver X receptor in cholesterol metabolism","volume":"204","author":"Zhao","year":"2010","journal-title":"J Endocrinol"},{"key":"10.1016\/j.apsb.2022.01.011_bib316","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrd4280","article-title":"Liver X receptors in lipid metabolism: opportunities for drug discovery","volume":"13","author":"Hong","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2022.01.011_bib317","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.tips.2012.03.013","article-title":"Liver X receptor biology and pharmacology: new pathways, challenges and opportunities","volume":"33","author":"Jakobsson","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2022.01.011_bib318","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1073\/pnas.0830671100","article-title":"Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue","volume":"100","author":"Laffitte","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.01.011_bib319","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3892\/mmr.2012.758","article-title":"Role of liver X receptors in cholesterol efflux and inflammatory signaling (review)","volume":"5","author":"Zhu","year":"2012","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.apsb.2022.01.011_bib320","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1101\/gad.850400","article-title":"Role of LXRs in control of lipogenesis","volume":"14","author":"Schultz","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.apsb.2022.01.011_bib321","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1194\/jlr.M300135-JLR200","article-title":"The LXR ligand T0901317 induces severe lipogenesis in the db\/db diabetic mouse","volume":"44","author":"Chisholm","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib322","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.2337\/diabetes.53.suppl_3.S75","article-title":"Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells","volume":"53 Suppl 3","author":"Efanov","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.01.011_bib323","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1194\/jlr.M300450-JLR200","article-title":"Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator","volume":"45","author":"Miao","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib324","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1074\/jbc.M411420200","article-title":"The liver X receptor ligand T0901317 decreases amyloid beta production in\u00a0vitro and in a mouse model of Alzheimer's disease","volume":"280","author":"Koldamova","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib325","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1159\/000358675","article-title":"Insulin-sensitizing effect of LXR agonist T0901317 in high-fat fed rats is associated with restored muscle GLUT4 expression and insulin-stimulated AS160 phosphorylation","volume":"33","author":"Baranowski","year":"2014","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.apsb.2022.01.011_bib326","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1007\/s11064-011-0513-3","article-title":"Activation of liver X receptor decreases BACE1 expression and activity by reducing membrane cholesterol levels","volume":"36","author":"Cui","year":"2011","journal-title":"Neurochem Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib327","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2164-13-50","article-title":"Genome-wide landscape of liver X receptor chromatin binding and gene regulation in human macrophages","volume":"13","author":"Pehkonen","year":"2012","journal-title":"BMC Genom"},{"key":"10.1016\/j.apsb.2022.01.011_bib328","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1124\/mol.106.022608","article-title":"Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting","volume":"70","author":"Quinet","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2022.01.011_bib329","doi-asserted-by":"crossref","first-page":"10021","DOI":"10.1074\/jbc.M108225200","article-title":"A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux","volume":"277","author":"Sparrow","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib330","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1194\/jlr.M400257-JLR200","article-title":"Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor","volume":"45","author":"Quinet","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib331","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1021\/jm800799q","article-title":"Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis","volume":"51","author":"Wrobel","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib332","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1194\/jlr.M900037-JLR200","article-title":"LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse","volume":"50","author":"Quinet","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib333","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1021\/acs.jmedchem.6b00176","article-title":"Identification and in\u00a0vivo evaluation of liver X receptor beta-selective agonists for the potential treatment of Alzheimer's disease","volume":"59","author":"Stachel","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib334","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.bmcl.2015.04.080","article-title":"Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptor beta-selective agonists","volume":"25","author":"Koura","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2022.01.011_bib335","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.bmcl.2015.01.047","article-title":"Design and discovery of 2-oxochromene derivatives as liver X receptor beta-selective agonists","volume":"25","author":"Matsuda","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2022.01.011_bib336","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1016\/j.bmc.2016.05.048","article-title":"Discovery of a 2-hydroxyacetophenone derivative as an outstanding linker to enhance potency and beta-selectivity of liver X receptor agonist","volume":"24","author":"Koura","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib337","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1021\/acs.jmedchem.5b02029","article-title":"Discovery of a novel, orally efficacious liver X receptor (LXR) beta agonist","volume":"59","author":"Zheng","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib338","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1016\/j.bmcl.2016.08.089","article-title":"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core","volume":"26","author":"Tice","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2022.01.011_bib339","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1124\/jpet.114.219923","article-title":"Pharmacological characterization of a novel liver X receptor agonist with partial LXRalpha activity and a favorable window in nonhuman primates","volume":"352","author":"Kirchgessner","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2022.01.011_bib340","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.bmcl.2014.11.029","article-title":"Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRbeta","volume":"25","author":"Kick","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2022.01.011_bib341","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1021\/acsmedchemlett.6b00234","article-title":"Discovery of highly potent liver X receptor beta agonists","volume":"7","author":"Kick","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2022.01.011_bib342","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cmet.2016.07.016","article-title":"Beneficial and adverse effects of an LXR agonist on uman lipid and lipoprotein metabolism and circulating neutrophils","volume":"24","author":"Kirchgessner","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2022.01.011_bib343","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/0091270009335768","article-title":"Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants","volume":"49","author":"Katz","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2022.01.011_bib344","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.atherosclerosis.2010.04.025","article-title":"LXRalpha regulates human CETP expression in\u00a0vitro and in transgenic mice","volume":"212","author":"Honzumi","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.apsb.2022.01.011_bib345","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cmet.2014.10.001","article-title":"The LXR\u2013Idol axis differentially regulates plasma LDL levels in primates and mice","volume":"20","author":"Hong","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2022.01.011_bib346","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1750-1326-2-20","article-title":"Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment","volume":"2","author":"Lefterov","year":"2007","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.apsb.2022.01.011_bib347","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.mcn.2007.01.011","article-title":"The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease","volume":"34","author":"Riddell","year":"2007","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib348","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.1523\/JNEUROSCI.1051-10.2010","article-title":"Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice","volume":"30","author":"Fitz","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib349","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1523\/JNEUROSCI.6546-10.2011","article-title":"Critical role of astroglial apolipoprotein E and liver X receptor-alpha expression for microglial Abeta phagocytosis","volume":"31","author":"Terwel","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib350","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.neurobiolaging.2009.07.005","article-title":"Liver X receptor activation restores memory in aged AD mice without reducing amyloid","volume":"32","author":"Vanmierlo","year":"2011","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.apsb.2022.01.011_bib351","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuroscience.2012.02.047","article-title":"Liver X receptor activation attenuates inflammatory response and protects cholinergic neurons in APP\/PS1 transgenic mice","volume":"210","author":"Cui","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.apsb.2022.01.011_bib352","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3233\/JAD-132789","article-title":"Improvement of memory deficits and amyloid-beta clearance in aged APP23 mice treated with a combination of anti-amyloid-beta antibody and LXR agonist","volume":"41","author":"Fitz","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2022.01.011_bib353","doi-asserted-by":"crossref","first-page":"e0172161","DOI":"10.1371\/journal.pone.0172161","article-title":"Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice","volume":"12","author":"Carter","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.01.011_bib354","doi-asserted-by":"crossref","first-page":"15962","DOI":"10.1523\/JNEUROSCI.2085-11.2011","article-title":"Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's beta-amyloidosis mouse model","volume":"31","author":"Wesson","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib355","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bbalip.2011.08.014","article-title":"The LXR agonist GW3965 increases apoA-I protein levels in the central nervous system independent of ABCA1","volume":"1821","author":"Stukas","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2022.01.011_bib356","doi-asserted-by":"crossref","first-page":"e0145467","DOI":"10.1371\/journal.pone.0145467","article-title":"Role of liver X receptor in AD pathophysiology","volume":"10","author":"Sandoval-Hernandez","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.01.011_bib357","doi-asserted-by":"crossref","first-page":"21591","DOI":"10.1074\/jbc.M115.652008","article-title":"Combined liver X receptor\/peroxisome proliferator-activated receptor gamma agonist treatment reduces amyloid beta levels and improves behavior in amyloid precursor protein\/presenilin 1 mice","volume":"290","author":"Skerrett","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib358","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12031-015-0665-8","article-title":"Liver X receptor agonist modifies the DNA ethylation profile of synapse and neurogenesis-related genes in the triple transgenic mouse model of Alzheimer's disease","volume":"58","author":"Sandoval-Hernandez","year":"2016","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.apsb.2022.01.011_bib359","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.neulet.2016.04.007","article-title":"LXR activation protects hippocampal microvasculature in very old triple transgenic mouse model of Alzheimer's disease","volume":"621","author":"Sandoval-Hernandez","year":"2016","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.apsb.2022.01.011_bib360","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1210\/er.2003-0023","article-title":"Coregulator function: a key to understanding tissue specificity of selective receptor modulators","volume":"25","author":"Smith","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.apsb.2022.01.011_bib361","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0960-0760(00)00104-7","article-title":"Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology","volume":"74","author":"Katzenellenbogen","year":"2000","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib362","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2007.11.002","article-title":"Tamoxifen: catalyst for the change to targeted therapy","volume":"44","author":"Jordan","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.apsb.2022.01.011_bib363","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/dta.2908","article-title":"Analysis of supplements available to UK consumers purporting to contain selective androgen receptor modulators","volume":"13","author":"Leaney","year":"2021","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.apsb.2022.01.011_bib364","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1111\/bph.15286","article-title":"Screening for liver X receptor modulators: where are we and for what use?.","volume":"178","author":"Bunay","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2022.01.011_bib365","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.mce.2011.08.036","article-title":"Selective liver X receptor modulators (SLiMs): what use in human health?.","volume":"351","author":"Viennois","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.apsb.2022.01.011_bib366","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bbrc.2016.09.036","article-title":"Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease","volume":"479","author":"Griffett","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2022.01.011_bib367","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/cb300541g","article-title":"A liver-selective LXR inverse agonist that suppresses hepatic steatosis","volume":"8","author":"Griffett","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib368","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bbrc.2013.11.077","article-title":"Action mechanisms of liver X receptors","volume":"446","author":"Gabbi","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2022.01.011_bib369","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/mol.116.105213","article-title":"Identification of a novel liver X receptor agonist that regulates the expression of key cholesterol homeostasis genes with distinct pharmacological characteristics","volume":"91","author":"Li","year":"2017","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2022.01.011_bib370","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1210\/me.2008-0041","article-title":"Selective partial agonism of liver X receptor alpha is related to differential corepressor recruitment","volume":"22","author":"Phelan","year":"2008","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.apsb.2022.01.011_bib371","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1128\/MCB.23.16.5780-5789.2003","article-title":"Promoter-specific roles for liver X receptor\/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression","volume":"23","author":"Wagner","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib372","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00376-18","article-title":"Common and differential transcriptional actions of nuclear receptors liver X receptors alpha and beta in macrophages","volume":"39","author":"Ramon-Vazquez","year":"2019","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib373","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.mam.2009.02.002","article-title":"Oxysterol signaling links cholesterol metabolism and inflammation via the liver X receptor in macrophages","volume":"30","author":"Torocsik","year":"2009","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.apsb.2022.01.011_bib374","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s42003-019-0675-0","article-title":"Structural analysis identifies an escape route from the adverse lipogenic effects of liver X receptor ligands","volume":"2","author":"Belorusova","year":"2019","journal-title":"Commun Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib375","doi-asserted-by":"crossref","first-page":"112793","DOI":"10.1016\/j.ejmech.2020.112793","article-title":"Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors","volume":"206","author":"Chen","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib376","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nsmb.2778","article-title":"Structure of the retinoid X receptor alpha\u2013liver X receptor beta (RXRalpha\u2013LXRbeta) heterodimer on DNA","volume":"21","author":"Lou","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib377","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.str.2017.07.019","article-title":"Synergistic regulation of coregulator\/nuclear receptor interaction by ligand and DNA","volume":"25","author":"de Vera","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.apsb.2022.01.011_bib378","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3390\/ijms19041260","article-title":"The role of PPAR and its cross-talk with CAR and LXR in obesity and atherosclerosis","volume":"19","author":"Xu","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2022.01.011_bib379","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1210\/me.2002-0191","article-title":"Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling","volume":"17","author":"Ide","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.apsb.2022.01.011_bib380","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1210\/me.2002-0190","volume":"17","author":"Yoshikawa","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.apsb.2022.01.011_bib381","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.addr.2010.07.006","article-title":"Functional crosstalk of CAR\u2013LXR and ROR\u2013LXR in drug metabolism and lipid metabolism","volume":"62","author":"Xiao","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2022.01.011_bib382","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ymgme.2004.07.007","article-title":"T0901317 is a dual LXR\/FXR agonist","volume":"83","author":"Houck","year":"2004","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.apsb.2022.01.011_bib383","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1074\/jbc.M209629200","article-title":"A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha) versus liver X receptor","volume":"278","author":"Thomas","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.011_bib384","doi-asserted-by":"crossref","first-page":"e0162384","DOI":"10.1371\/journal.pone.0162384","article-title":"Identification of a chrysanthemic ester as an apolipoprotein E inducer in astrocytes","volume":"11","author":"Fan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.01.011_bib385","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1194\/jlr.M081851","article-title":"Small molecule inducers of ABCA1 and apoE that act through indirect activation of the LXR pathway","volume":"59","author":"Fan","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.01.011_bib386","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13041-020-00609-1","article-title":"Axl receptor tyrosine kinase is a regulator of apolipoprotein E","volume":"13","author":"Zhao","year":"2020","journal-title":"Mol Brain"},{"key":"10.1016\/j.apsb.2022.01.011_bib387","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.chembiol.2016.10.015","article-title":"Bioactive compound screen for pharmacological enhancers of apolipoprotein E in primary human astrocytes","volume":"23","author":"Finan","year":"2016","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib388","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.chembiol.2020.09.002","article-title":"Photoaffinity labeling and quantitative chemical proteomics identify LXRbeta as the functional target of enhancers of astrocytic apoE","volume":"28","author":"Seneviratne","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2022.01.011_bib389","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1016\/j.bmcl.2014.05.054","article-title":"ApoE secretion modulating bromotyrosine derivative from the Australian marine sponge Callyspongia sp","volume":"24","author":"Tian","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2022.01.011_bib390","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1021\/acsptsci.0c00149","article-title":"Discovery of nonlipogenic ABCA1 inducing compounds with potential in Alzheimer's disease and type 2 diabetes","volume":"4","author":"Ben Aissa","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.apsb.2022.01.011_bib391","doi-asserted-by":"crossref","first-page":"103287","DOI":"10.1016\/j.ebiom.2021.103287","article-title":"Metabolomic analysis of a selective ABCA1 inducer in obesogenic challenge provides a rationale for therapeutic development","volume":"66","author":"Lewandowski","year":"2021","journal-title":"EBioMedicine"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383522000247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383522000247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:51:03Z","timestamp":1761929463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383522000247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":391,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2211383522000247"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2022.01.011","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remembering your A, B, C's: Alzheimer's disease and ABCA1","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2022.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}